Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have received an average recommendation of "Buy" from the seven analysts that are covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have covered the stock in the last year is $44.86.

REPL has been the subject of several recent research reports. Piper Sandler reduced their price target on Replimune Group to $43.00 in a research report on Monday, August 22nd. SVB Leerink reduced their price target on Replimune Group from $37.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday.

Institutional Trading of Replimune Group

A number of hedge funds have recently modified their holdings of REPL. Frazier Life Sciences Management L.P. purchased a new stake in shares of Replimune Group in the first quarter worth about $12,171,000. State Street Corp boosted its stake in shares of Replimune Group by 36.6% in the first quarter. State Street Corp now owns 1,712,037 shares of the company's stock worth $29,070,000 after buying an additional 458,420 shares during the last quarter. Bank of Montreal Can purchased a new stake in shares of Replimune Group in the second quarter worth about $3,781,000. Renaissance Technologies LLC boosted its stake in shares of Replimune Group by 352.4% in the first quarter. Renaissance Technologies LLC now owns 211,053 shares of the company's stock worth $3,584,000 after buying an additional 164,400 shares during the last quarter. Finally, Emerald Advisers LLC boosted its stake in shares of Replimune Group by 14.6% in the first quarter. Emerald Advisers LLC now owns 1,134,012 shares of the company's stock worth $19,256,000 after buying an additional 144,054 shares during the last quarter. Hedge funds and other institutional investors own 80.93% of the company's stock.

Replimune Group Trading Down 0.9 %

Replimune Group (NASDAQ:REPL – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.15). Analysts expect that Replimune Group will post -3.13 earnings per share for the current fiscal year.

Replimune Group Company Profile

(Get Rating)

Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.

Featured Articles

• Get a free copy of the StockNews.com research report on Replimune Group (REPL)
• 3 Stocks Growing Their Businesses for 2023
• China-Based EV Maker BYD Set For Big European, Japanese Expansion
• Is Illumina Still the Gamechanger in Genomics Sequencing?
• Here's What Makes Amazon a Sum-of-All-Parts Commerce Juggernaut
• FedEx Will Deliver Better News in 2023

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.